Brazil’s ANVISA approval process for foreign companies requires registering a medicinal product or medical device through ANVISA, Brazil’s national health surveillance agency, with the mandatory involvement of a locally established Brazilian company or representative. The process involves document submission, GMP certification, and regulatory review, and typically takes anywhere from several months to several years, depending on the product type and review pathway. Below, we break down the key questions foreign companies face when entering the Brazilian market.
What documents do foreign companies need for ANVISA registration?
Foreign companies applying for ANVISA registration must submit a comprehensive dossier that follows ANVISA’s specific formatting and content requirements, which are broadly aligned with the ICH CTD structure but include Brazil-specific elements. The exact documentation depends on the product category, but pharmaceutical registrations generally require administrative, quality, preclinical, and clinical modules.
Core documents typically required include:
- Administrative documentation: Proof of the product’s approval in its country of origin, Good Manufacturing Practice (GMP) certificates, and the legal authorization of the Brazilian local representative
- Quality module (Module 3 equivalent): Full pharmaceutical development data, manufacturing process descriptions, specifications, stability data, and container closure information
- Nonclinical and clinical data (Modules 4 and 5): Preclinical safety studies and clinical trial data supporting efficacy and safety
- Labeling: Product labeling in Portuguese, compliant with ANVISA’s specific requirements for package inserts and outer packaging
- Brazilian-specific forms: Petitions and declarations required by ANVISA’s electronic submission system, SOLICITA
All documents must be translated into Portuguese by a certified translator. ANVISA may also request additional data during the review process through formal queries, so maintaining organized, complete files from the outset significantly reduces back-and-forth delays.
What is the role of a Brazilian local representative in the ANVISA process?
A Brazilian local representative, known as a responsável técnico (technical responsible) or local agent, is legally required for any foreign company seeking ANVISA registration. This representative must be a company legally established in Brazil and is responsible for all regulatory communications with ANVISA on behalf of the foreign manufacturer.
The local representative carries significant legal responsibility. They submit the registration dossier, respond to ANVISA queries, maintain the product registration once approved, and are accountable for post-market surveillance obligations, including adverse event reporting and product recalls. ANVISA will not accept submissions directly from a foreign entity without this local presence.
Choosing the right local representative is a strategic decision. The representative must have the technical capacity to handle regulatory interactions and the legal standing to act as the marketing authorization holder in Brazil. Many foreign companies partner with a Brazilian distributor who also serves as the local representative, while others engage a dedicated regulatory affairs partner to manage this role independently of commercial arrangements. To learn more about how Starodub supports this process, visit our regulatory services overview.
How long does ANVISA approval take for foreign pharmaceutical companies?
ANVISA approval timelines for foreign pharmaceutical companies vary considerably based on the product type, review pathway, and application completeness. Standard review timelines for new drug registrations can range from 12 to 60 months, though priority review pathways can significantly reduce this to as little as 120 days for qualifying products.
Several factors influence the total timeline:
- Application completeness: Incomplete dossiers or missing documents trigger formal queries that pause the review clock and can add months to the process
- Product complexity: Biologics, new chemical entities, and combination products typically require longer review periods than generics or similar products
- GMP inspection scheduling: If ANVISA requires an on-site inspection of the foreign manufacturing facility, scheduling and completing that inspection adds time
- Queue position: ANVISA manages a large volume of submissions, and standard review timelines are affected by the overall workload of the relevant technical unit
Planning for a minimum of 18 to 24 months for a standard new product registration is a reasonable baseline for foreign companies, with biologics and ATMPs often taking longer.
What is ANVISA’s priority review pathway and who qualifies?
ANVISA’s priority review pathway, established under Resolution RDC 204/2017 and its updates, allows qualifying products to receive accelerated evaluation with a target review time of 120 days rather than the standard multi-year timeline. This pathway is designed to expedite access to products that address significant unmet medical needs in Brazil.
Products that may qualify for priority review include:
- Medicines for rare diseases (orphan drugs)
- Products for diseases with no existing approved treatment in Brazil
- Products that represent a significant therapeutic advance over currently available treatments
- Products already approved under accelerated or priority pathways by reference regulatory authorities such as the FDA, EMA, or Health Canada
- Products included in Brazil’s national strategic health programs
To access the priority pathway, companies must submit a formal request to ANVISA before or alongside the registration dossier, demonstrating how the product meets the qualifying criteria. ANVISA evaluates this request separately and grants or denies priority status. Even with priority designation, the quality of the dossier remains critical, as deficiencies will still generate queries and delay final approval.
How does ANVISA’s GMP inspection process work for foreign manufacturers?
ANVISA requires that all manufacturing sites producing products for the Brazilian market comply with Good Manufacturing Practices, and for foreign manufacturers, this means obtaining a Certificate of Good Manufacturing Practices (CBPF) issued or recognized by ANVISA. This GMP certification is a prerequisite for product registration and must remain valid throughout the product’s commercial life in Brazil.
ANVISA accepts GMP certificates issued by regulatory authorities it recognizes as reference agencies, including the EMA, FDA, Health Canada, and several others. If a valid GMP certificate from a recognized authority already exists for the manufacturing site, ANVISA may grant certification based on that document review without conducting its own inspection, a process known as recognition or reliance.
However, if the manufacturing site is not covered by a recognized authority’s GMP certificate, ANVISA will schedule its own inspection. These inspections are conducted by ANVISA inspectors who travel to the facility, and the scheduling process itself can take considerable time. Foreign manufacturers should ensure their sites are inspection-ready and that all relevant documentation, including batch records, validation data, and quality system documentation, is available and organized in advance.
GMP certificates must be renewed periodically, and any significant changes to the manufacturing site or processes may trigger a new inspection requirement. Keeping GMP documentation current is an ongoing obligation, not a one-time milestone.
What are the most common reasons ANVISA rejects or delays foreign applications?
ANVISA delays or rejects foreign applications most commonly due to incomplete or non-compliant documentation, GMP certification gaps, and failure to meet Brazil-specific formatting and labeling requirements. Understanding these pitfalls in advance dramatically improves the chances of a smooth review.
The most frequent causes of delays and rejections include:
- Incomplete dossiers: Missing studies, inadequate stability data for Brazilian climatic conditions (Zone IVb), or gaps in the quality module are among the leading causes of formal queries
- Non-compliant labeling: Labels and package inserts that do not meet ANVISA’s Portuguese-language requirements or mandatory content rules are a common deficiency
- GMP certificate issues: Expired certificates, sites not covered by the submitted GMP documentation, or certificates from non-recognized authorities create significant delays
- Inadequate local representative documentation: Errors or gaps in the legal authorization of the Brazilian representative can result in administrative rejection before technical review even begins
- Failure to address queries promptly: ANVISA sets deadlines for responding to technical queries; missing these deadlines can result in archiving of the application
- Regulatory changes mid-process: ANVISA updates its requirements periodically, and applications submitted under older guidelines may need to be adapted during the review period
Proactive preparation, including a gap analysis of the dossier against current ANVISA requirements before submission, is the most effective way to avoid these common pitfalls. You can learn more about our approach and background on the Starodub company page.
How Starodub supports your ANVISA registration strategy
Navigating the ANVISA approval process from outside Brazil is complex, and the stakes of a delayed or rejected application are high. We at Starodub provide end-to-end regulatory support for biopharmaceutical and medical device companies looking to enter the Brazilian market, drawing on our deep experience with international regulatory submissions and compliance requirements.
Here is how we can help:
- Dossier gap analysis and preparation: We review your existing documentation against current ANVISA requirements and identify gaps before submission, reducing the risk of queries and delays
- GMP compliance guidance: We advise on GMP certification pathways, help prepare for ANVISA inspections, and support site readiness assessments
- Regulatory strategy development: We assess whether your product qualifies for priority review and help build the strongest possible case for accelerated evaluation
- Local representative coordination: We work alongside your Brazilian local representative or help you identify the right partner to fulfill this critical role
- Lifecycle management: From initial registration through renewals, variations, and post-market obligations, we provide ongoing regulatory support to keep your product on the Brazilian market
If you are planning a Brazil market entry or need support with an existing ANVISA submission, contact us today to discuss how we can help you navigate the process efficiently and confidently.
Related Articles
- How do you handle regulatory strategy pivots during development?
- Why is regulatory affairs important for biotech companies?
- What regulatory affairs services do medical device companies need?
- What are the emerging global medical device regulatory trends for 2026?
- How do you maintain regulatory compliance after approval?
